- Home
- Meetings
- EHA-EBMT 2nd European CAR T Cell Meeting
- Meeting program
Meeting program
Regulatory workshop on the development of CAR T cells
A regulatory workshop on the development of CAR-T Cells will be organized by the consortia EURE-CART and CARAMBA on January 30, 2020. This workshop will take place the morning prior to the 2nd European CAR T cell meeting, in the same meeting venue, the Melia Sitges Hotel. For more information and to register for the workshop, please visit this website. Please note: registration for the 2nd European CAR T Cell Meeting is NOT included in the registration for the workshop.
2nd European CAR T cell meeting - Program
The meeting program begins on Thursday, January 30 at 12:00 and ends on Saturday, February 1 at 16:45.
Please visit this page regularly for the most up-to-date program.
Thursday, January 30
12:00 - 12:15 Opening ceremony
Room: Auditorium
- Opening & welcome
H Einsele & C Chabannon (Chairs of the Scientific Program Committee) - About EHA/EBMT and their activities
J Gribben (President EHA) & N Kröger (President EBMT)
12:15 - 12:45 Session 1: Keynote Lecture
Room: Auditorium
Chairs: H Einsele & C Chabannon (Chairs of the Scientific Program Committee)
- Informed design of engineered T cell therapies for cancer
S Riddell (United States)
12:45 - 14:15 Session 2: Indications for CAR T cell therapy
Room: Auditorium
Chairs: J Gribben (President EHA) & N Kröger (President EBMT)
- Acute leukemia
A Nagler (Israel) - Myeloma
H Einsele (Germany) - Lymphoma
C Thieblemont (France)
14:15 - 15:15 Session 3: Improving the efficacy and safety profile
Room: Auditorium
Chairs: M Hudecek (Germany) & C MacKall (United States)
- Targeted genomic insertion
DH Büsch (Germany) - Virus-free gene transfer & genome editing
M Hudecek (Germany) - Adapter/Uni-CARs
G Ehninger (Germany)
15:15 - 15:45 Coffee break & Industry theater session
15:45 - 16:15 Session 4: Keynote lecture
Room: Auditorium
Chairs: A Baruchel (France) & MHM Heemskerk (The Netherlands)
- Engineering next generation CAR T cells to overcome resistance
C MacKall (United States)
16:15 - 17:15 Session 5: CAR T in pediatrics
Room: Auditorium
Chairs: A Baruchel (France) & MHM Heemskerk (The Netherlands)
- Neuroblastoma
F Locatelli (Italy) - Post-transplant relapse - Second SCT or CAR T cells
P Bader (Germany) - Bispecific CAR T cells
PJ Amrolia (United Kingdom)
17:15 - 17:45 Session 6: Keynote Lecture
Room: Auditorium
Chairs: H Einsele & C Chabannon (Chairs of the Scientific Program Committee)
- Improved CAR T cell approaches for lymphoid malignancies
MA Pule (United Kingdom)
17:45 - 18:45 Session 7: Best Abstracts & Flash Talks - Part I
Room: Auditorium
Chairs: H Einsele & C Chabannon (Chairs of the Scientific Program Committee)
Oral presentations
- O1.1 PHASE 1B RESULTS FROM CARTITUDE-1: A PHASE 1B/2 STUDY OF JNJ-4528, A CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY DIRECTED AGAINST B-CELL MATURATION ANTIGEN (BCMA), IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (R/R MM)
D Madduri (United States) - O1.2 IMMUNOTHERAPY OF TRIPLE NEGATIVE BREAST CANCER WITH ROR1 CAR T CELLS IS AUGMENTED IN COMBINATION WITH THE TGF-ß INHIBITOR SD-208
RM Monjezi (Germany) - O1.3 CAR T CELL ENTRY INTO TUMOR ISLETS IS A TWO-STEP PROCESS DEPENDENT ON IFNΓ AND ICAM-1
E Donnadieu (France)
Oral flash talks
- O1.4 INTEGRATED DRUG PROFILING AND CRISPR SCREENING IDENTIFY ESSENTIAL PATHWAYS FOR CAR T CELL CYTOTOXICITY
M Keränen (Finland) - O1.5 A NEW PROMISING THIRD GENERATION CAR-CD30 T-CELL THERAPY FOR CD30+ LYMPHOMAS
B De Angelis (Italy) - O1.6 ENGINEERING CYTOKINE-INDUCED KILLER (CIK) CELLS TO EXPRESS CD33.CAR BY USING A NOVEL SLEEPING BEAUTY TRANSPOSON SYSTEM
S Tettamanti (Italy) - O1.7 HAMPERING TUMOR GLYCOSYLATION IMPROVES THE EFFICACY OF CAR-T CELLS AGAINST SOLID TUMORS
C Sirini (Italy) - O1.8 PHASE I STUDY OF DONOR-DERIVED CD19 CAR CYTOKINE INDUCED KILLER (CIK) CELLS ENGINEERED WITH SLEEPING BEAUTY TRANSPOSON FOR RELAPSED B-CELL LEUKEMIA
CF Magnani (Italy) - O1.9 EARLIER STEROID USE WITH AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA
MJ Kersten (The Netherlands)
18:45 - 19:30 Satellite symposium by Celgene
Recent advances in CAR T cell therapy for haematological malignancies
Room: Auditorium
Chair: J Abramson (United States)
- CD19 Targeting CAR T therapy in DLBCL and CLL: Evolving landscape
J Abramson (United States) - Overview of the CAR T cell approaches in MM
MV Mateos (Spain)
19:30 - 20:30 Welcome reception & poster session
Friday, January 31
08:30 - 09:30 Session 8: Latest clinical & pre-clinical pipeline - Part I
Room: Auditorium
Chairs: JHE Kuball (The Netherlands) & B Levine (United States)
- ROR1 CAR T cell therapy in CLL and solid tumors
J Specht (United States) - Novel CAR targets for multiple myeloma
N Hosen (Japan) - CD123 for AML and CNS tumors
J Abramson (United States)
09:30 - 10:00 Session 9: Keynote lecture
Room: Auditorium
Chairs: JHE Kuball (The Netherlands) & B Levine (United States)
- Updates in CAR T cell therapy
C June (United States)
10:00 - 11:00 Session 10: Latest clinical & pre-clinical pipeline - Part II
Room: Auditorium
Chairs: JHE Kuball (The Netherlands) & B Levine (United States)
- CAR30 memory T cells for Hodgkin and T cell lymphoma
J Briones (Spain) - L1CAM-specific CAR T cell therapy for childhood neuroblastoma
A Künkele (Germany) - iPS CARs
M Themeli (The Netherlands)
11:00 - 11:30 Coffee break
11:30 - 12:30 Session 11: Best Abstracts & Flash Talks - Part II
Room: Auditorium
Chairs: M Hudecek (Germany) & A Urbano-Ispizua (Spain)
Oral presentations
- O2.1 CAR T CELLS FOR FUNGAL INFECTIONS: NOVEL CAR T CELLS SHOW ENHANCED SPECIFICITY AND REACTIVITY TOWARDS ASPERGILLUS FUMIGATUS
M Seif (Germany) - O2.2 A PLATFORM FOR CAR-TREG GENERATION FOR AUTOIMMUNE DISEASES
M Doglio (Italy) - O2.3 ARE CAR TS THE SAME? EVIDENCE FROM EUROPEAN HTA REVIEWS
S Lykopoulos (United Kingdom)
Oral flash talks
- O2.4 CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T) IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA WITH EXTRAMEDULLARY DISEASE
A Alonso-Saldrigues (Spain) - O2.5 DEVELOPMENT OF A DIGITAL-PCR ASSAY FOR PRECISE QUANTIFICATION OF ADOPTIVELY TRANSFERRED CD19-CAR-T CELLS AFTER TREATMENT WITH AXICABTAGENE CILOLEUCEL (AXI-CEL)
C Berger (Germany) - O2.6 DIFFERENTIAL IMPACT OF SOLUBLE NKG2DL ON NKG2D CAR T CELLS´ ABILITY TO TARGET TUMOR CELLS
A Fernandez (Spain) - O2.7 NANOBODY BASED TRI-SPECIFIC CHIMERIC ANTIGEN RECEPTOR TO TREAT ACUTE MYELOID LEUKAEMIA
W Hazelton (United Kingdom) - O2.8 LONG-TERM FOLLOW-UP OF A PHASE 1, FIRST-IN-HUMAN OPEN-LABEL STUDY OF LCAR-B38M, A STRUCTURALLY DIFFERENTIATED CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY TARGETING B-CELL MATURATION ANTIGEN (BCMA), IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
J Liu (China) - O2.9 EDUCATION FOR THE CLINICAL IMPLEMENTATION OF CAR-T CELL THERAPY USING SIMULATION BASED EDUCATION FOR EVIDENCE BASED MANAGEMENT OF CHIMERIC ANTIGEN RECEPTOR T-CELL RELATED CYTOKINE RELEASE SYNDROME AND ENCEPHALOPATHY SYNDROME
A Harden (United States)
12:30 - 13:00 Session 12: Keynote lecture
Room: Auditorium
Chairs: M Hudecek (Germany) & A Urbano-Ispizua (Spain)
- Current CAR T trial activities in China
JX Wang (China)
13:00 - 14:30 Lunch break
13:45 - 14:30 Satellite symposium by Gilead
Redefining survival in DLBCL: The role of CAR T
Room: Auditorium
Chair: A Sureda (Spain)
- Defining long-term survival in DLBCL
A Sureda (Spain) - How is cell therapy changing outcomes in 3L+ DLBCL?
R Sanderson (United Kingdom) - Long-term survivorship with R/R DLBCL: A patient perspective
N Bolaños (Spain) - Summary and close
A Sureda (Spain)
14:30 - 15:00 Session 13: Keynote lecture
Room: Auditorium
Chairs: I Yakoub-Agha (France) & DH Büsch (Germany)
- The emergence of synthetic immunity
M Sadelain (United States)
15:00 - 16:00 Session 14: CAR effector cells
Room: Auditorium
Chairs: I Yakoub-Agha (France) & DH Büsch (Germany)
- CAR expressing NK cells for cancer retargeting
K Rezvani (United States) - Allogeneic CAR T cells
W Qasim (United Kingdom) - CAR-NK cells as off-the-shelf therapeutics bridging innate and adaptive immunity
WS Wels (Germany)
16:00 - 17:00 Session 15: Optimizing CAR T treatment
Room: Auditorium
Chairs: M Mohty (France) & P Pedrazzoli (Italy)
- Microbiome
M van den Brink (United States) - Visualizing CAR T cells at work
JB Huppa (Austria) - Improving CAR T cells in solid tumors
S Guedan Carrio (Spain)
17:00 - 17:30 Coffee break
17:05 - 17:30 Industry theater session by BD Biosciences
From discovery to the clinic: Tools for immuno-oncology and cell therapy development
Room: Tramuntana 1
17:30 - 19:00 Session 16: CAR T regulatory session
Room: Auditorium
Chairs: N Bolaños (Spain) & W Herr (Germany)
- Marketing authorization for CAR T cells - The EMA perspective
M Schüssler-Lenz (Germany) - Creating a country-wide selection algorithm - The Austrian experience
U Jäger (Austria) - PASS and PAES: The need for registration, short- and long-term follow-up of patients treated with gene therapy medicinal products
C Chabannon (France) - Access and reimbursement CAR-T: Patients' perspective
BJ Verhoeven (The Netherlands)
19:00 - 19:45 Satellite symposium by Novartis
CAR-T experience: From trial to real world evidence
Room: Auditorium
Chair: C Solano (Spain)
- Trials design with CAR-T
F Ciceri (Italy) - CART Experience in DLBCL
I Avivi (Israel)
Saturday, February 1
08:30 - 09:45 Session 17: European grants / projects
Room: Auditorium
Chairs: C Chomienne (France) & C Bonini (Italy)
- CARAMBA (H2020, SLAMF7 CAR T)
M Hudecek (Germany) - EURE-CART (H2020, CD44v6 CAR T)
F Ciceri (Italy) - CARAT (H2020; CAR T manufacturing)
MW Assenmacher (Germany) - imSAVAR
U Köhl (Germany)
08:30 - 09:45 Session 18: Nurses session - Patient care - Part I
Room: Tramuntana 3
Chairs: E Aerts (Switzerland) & J Murray (United Kingdom)
- The science of IEC and what is new
E Vickers (United Kingdom) - Solid tumors and IEC
T Garcia Lopez (United Kingdom) - Clinical trial updates
I Yakoub-Agha (France)
08:30 - 09:45 Session 19: Data managers session - Part I
Room: Tramuntana 2
Chair: JH van Biezen (The Netherlands)
- Content of the Advanced Cellular Therapies form
C Chabannon (France) - CAR T data collection - CIBMTR experience
MC Pasquini (United States)
09:45 - 10:15 Coffee break
09:50 - 10:15 Industry theater session by Gilead
The increasing reach of CAR T cell therapy: the Kite story
Room: Tramuntana 1
10:15 - 12:00 Session 20: Round table discussion: Management of side effects
Room: Auditorium
Chair: M Mohty (France)
- B-cell aplasia and hypogammaglobulinemi
A Baruchel (France) - Cytopenia
M Subklewe (Germany) - Disease and age groups
MJ Kersten (The Netherlands) - Guidelines
I Yakoub-Agha (France) - Round table discussion
All speakers
10:15 - 12:00 Session 21: Nurses session - Patient care - Part II
Room: Tramuntana 3
Chairs: E Aerts (Switzerland) & J Murray (United Kingdom)
- Apheresis in adults and pediatrics
D Hutt (Israel) - Real world experience of commercial IEC
AA Hereu (Spain) - Managing expectations
M Kenyon (United Kingdom) - Psychology and CAR T
S Chaturvedi (United Kingdom) - CAR T ineligible: What now?
MP Nogué (Spain)
10:15 - 12:00 Session 22: Data managers session - Part II
Room: Tramuntana 2
Chair: MC Pasquini (United States)
- Follow-up of CAR T cell treatments - The EMA Registry Initiative
JHE Kuball (The Netherlands) - PASS studies
JH van Biezen (The Netherlands) - Toxicities in CAR T therapy - Recognition and management
R Benjamin (United Kingdom)
12:00 - 13:00 Lunch break
13:00 - 14:30 Session 23: Round table discussion: Implementation of CAR T cells in the real world
Room: Auditorium
Chairs: C Rössig (Germany) & A Nagler (Israel)
Round table discussion
- S Mielke (Sweden)
- GA Salles (France)
- M Mohty (France)
- MC Pasquini (United States)
- Round table discussion
All speakers
13:00 - 14:30 Session 24: Physicians session - Manufacturing of CAR T cell in an academic setting
Room: Tramuntana 2
Chairs: U Köhl (Germany) & A Urbano-Ispizua (Spain)
- London group
C Roddie (United Kingdom) - Tel Aviv group
E Jacoby (Israel) - Barcelona group
M Juan Otero (Spain) - Frankfurt group
HB Bönig (Germany)
13:00 - 14:30 Session 25: Nurses session - Patient care - Part III
Room: Tramuntana 3
Chairs: E Aerts (Switzerland) & J Murray (United Kingdom)
- Nursing guidelines and network for IEC
RL Ellard (United Kingdom) - Nurse training program
RE Clout (United Kingdom) - The patient experience
LA Latorre (Spain) - Relapse post CAR T options
M Berquier (France)
14:30 - 15:00 Coffee break
15:00 - 16:30 Session 26: Manufacturing of CAR T cell in an industrial setting
Room: Auditorium
Chairs: J Gribben (President EHA) & N Kröger (President EBMT)
- Academia - Industry partnering to develop innovative CAR T cells
B Levine (United States) - Point-of-care manufacturing (POC) as an alternative to central manufacturing
G Rauser (Germany) - Expanding CAR T into the commercial setting: Planning for success
B Dudek (Gilead) - Building a Swiss timepiece: The evolution of global CAR T industrial manufacturing
D Ledergerber (Novartis)
15:00 - 16:30 Session 27: Nurses session - Patient care - Part IV
Room: Tramuntana 3
Chair: J Murray (United Kingdom)
Panel discussion & meet-the-experts
- M Ní Chonghaile (Ireland)
- E Aerts (Switzerland)
- D Hutt (Israel)
- RL Ellard (United Kingdom)
The last nurses session will offer the opportunity for our participants to attend a special Panel Discussion hosted by 5 International experts in the field of CAR-T therapy. Questions and practice challenges from throughout the day will be discussed and debated. We want to encourage the involvement and contribution of our participants to create stimulating and interesting discussions and generate new knowledge and approaches to Nursing care in the CAR-T setting.
Following the Panel Discussion we will then break out onto 4 ‘meet-the-expert’ tables where participants will explore a specific theme, and bring their own questions and topics to discuss in a more intimate environment. Participants will rotate from table to table every 10 minutes.
15:00 - 16:30 Session 28: CAR T health technology assessment: What is the value of CAR T?
Room: Tramuntana 2
Chairs: M Hudecek (Germany) & V Jacquemin (Servier)
- Reimbursment in Germany, DRG and CAR T
C Haag (Germany) - Bringing CAR T to patients: Delivering on the promise and the value of cell and gene therapies
E Ostuni (Novartis) - How to assess the value of CAR T: Challenges of P&R from an industry perspective
J Sindern (Janssen) - HTA for CAR T in hematologic malignancies from a societal perspective
C Uyl-de Groot (The Netherlands)
16:30 - 16:45 Closing remarks
Room: Auditorium
- H Einsele & C Chabannon (Chairs of the Scientific Program Committee)
Back